- Trial phase
- Phase 3
- Time to market
- The Phase 3 primary completion date is estimated around December 2027, with study completion around April 2028. If results are positive, an FDA submission would follow, putting a potential approval decision no earlier than late 2028 or 2029.
- Why 3/10
- No hard, dated catalyst for cliramitug is scheduled within the next ~12 months. The Phase 3 DepleTTR-CM trial has a primary completion date estimated around December 2027, more than 12 months away. Additionally, Royalty Pharma holds only a 3-4% royalty interest in cliramitug, not the drug itself, making it a small component of a diversified royalty portfolio. The company's nearer-term binary catalyst is the November 27, 2026 PDUFA for neladalkib, a different drug entirely.
Cliramitug has no near-term catalyst for RPRX. The next meaningful event is the Phase 3 DepleTTR-CM topline readout, estimated around December 2027. RPRX investors should focus on nearer-term drivers: the November 27, 2026 PDUFA for neladalkib (a separate royalty asset) and the company's Q4 earnings. Cliramitug is a long-term call option within RPRX's portfolio, not a near-term trading catalyst.
Price Chart
Executive Summary
Cliramitug is a first-in-class antibody being developed by AstraZeneca (via its Alexion unit) to clear amyloid deposits from the heart in ATTR cardiomyopathy, a progressive and fatal disease. Phase 1/2 data showed a favorable safety profile and evidence of amyloid clearance. A large Phase 3 trial (DepleTTR-CM) is fully enrolled with results expected around late 2027 or 2028. Royalty Pharma (RPRX) is not the drug's developer; in July 2026 it acquired a 3-4% royalty interest in cliramitug from Neurimmune for up to $425 million. For RPRX, cliramitug is a long-term portfolio contributor with no near-term binary catalyst, and the royalty is a small slice of a diversified book of biopharma royalties.
How It Works
Cliramitug is an intravenous antibody therapy designed to clear toxic protein clumps (amyloid deposits) from the heart. In ATTR cardiomyopathy, the protein transthyretin misfolds and builds up in the heart muscle, stiffening it and leading to heart failure. Cliramitug works by binding to these misfolded deposits and flagging them for removal by the immune system, potentially reversing the damage rather than just slowing new buildup.
Trial Status
The pivotal Phase 3 DepleTTR-CM trial (NCT06183931) is active but no longer recruiting, having enrolled more than 1,100 adults with ATTR-CM across 212 sites in ~28 countries. Patients receive monthly intravenous infusions of cliramitug or placebo for at least two years and up to four years. The primary endpoint is a composite of all-cause mortality and cardiovascular clinical events. Phase 1 results published in NEJM (2023) showed no drug-related serious adverse events and dose-dependent reductions in cardiac amyloid burden. Long-term open-label extension data published in Nature Medicine (2026) showed sustained safety and further amyloid depletion.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 DepleTTR-CM topline readout (primary completion estimated December 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report